• Therapiegebiete
  • Für Patienten
NUBEQA in Doublet Combination

Now Approved in Doublet Combination: NUBEQA® + ADT for use in mHSPC patients
1

As the only androgen receptor inhibitor (ARI) approved by Swissmedic, NUBEQA® offers you the flexibility to treat your mHSPC patients either in combination with chemotherapy or without.1-8

NUBEQA table - with/out docetaxel

NUBEQA® Swiss Product information (full version) 

Please consult the complete product information at swissmedicinfo.ch regarding the use of NUBEQA®

German
French
Italian
ARANOTE – primary publication

ARANOTE – primary publication

Saad et al. J Clin Oncol. 2024 Dec 20;42(36):4271-4281.

LEARN MORE

Patients on Nubeqa® with low baseline PSA (<4.1 ng/mL) had a lower risk of radiological progression or death vs. patients with baseline PSA ≥21.3 ng/mL9

Fred Saad, MD, FRCS

Fred Saad, MD, shares phase 3 ARANOTE findings by disease volume

In this video, Fred Saad, MD, FRCS, shares key findings from the study, “Darolutamide plus ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC) by disease volume: Subgroup analysis of the phase 3 ARANOTE trial,” which was presented at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco, California.

WATCH VIDEO
ARANOTE – Subgroup analysis by disease volume

ARANOTE – Subgroup analysis by disease volume

Saad et al. J Clin Oncol. 2025 Feb 18;43(5):suppl

LEARN MORE

NUBEQA® delayed the decline in the HRQoL of mHSPC patients versus Placebo10

ARANOTE – Health-related quality of life (HRQoL) outcomes

ARANOTE – Health-related quality of life (HRQoL) outcomes

Morgans et al. J Clin Oncol. 2025;43(16):suppl.5004

LEARN MORE

NUBEQA® with low Drug-Drug Interaction (DDI) potentials

Find more about DDIs on the NUBEQA® page.
 

Materials & Resources for your practice

Find other publications about NUBEQA® and patient materials for your practice here.

*ARI = Androgen receptor inhibitor
ADT - Androgen deprivation therapy

 

References

  1. Nubeqa® Fachinformation,
    www.swissmedicinfo-pro.ch
    .
  2. Smith MR, et al. ARASENS Trial Investigators. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med 2022 386(12):1132–1142.
  3. Fizazi K, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 2019;380(13):1235–1246.
  4. Fizazi K, et al. Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. N Engl J Med 2020;383(11):1040–1049.
  5. Saad F, et al. Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial. J Clin Oncol . 2024 Dec 20;42(36):4271-4281.
  6. Erleada® Fachinformation,
    www.swissmedicinfo-pro.ch
    .
  7. Xtandi® Fachinformation,
    www.swissmedicinfo-pro.ch
    .
  8. Zytiga® Fachinformation,
    www.swissmedicinfo-pro.ch
    .
  9. Saad F, et al. Prostate-specific antigen response with darolutamide plus androgen-deprivationtherapy in patients with metastatic hormone sensitive prostate cancer in ARANOTE. Presentedat European Association of Urology; March 21–24, 2025; Madrid, Spain.
  10. Morgans AK et al. Health-related quality of life (HRQoL) outcomes with darolutamide in the phase 3 ARANOTE trial. 2025 ASCO (American Society of Clinical Oncology) Annual Meeting, Chicago USA, 30.5.–3.6. 2025, Abstract 5004. Oral Presentation by Dr. Alicia K. Morgans.
  11. Bolek H et al. Androgen receptor pathway inhibitors and drug-drug interactions in prostate cancer. ESMO Open. 2024 Nov;9(11):103736.

The referenced data, respectively publications, are available upon request.